Cas 83915-83-7 Lisinopril Dihydrate Pharmaceutical Receptor Antagonist Drugs Cardiovascular Api

Basic Information
Place of Origin: China
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Your demand
Delivery Time: Negotiation
Payment Terms: D/P, D/A, L/C, T/T
Supply Ability: Negotiation
Cas No: 83915-83-7 Ec No: 627-033-9
Name: Lisinopril Synonyms: (S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline Dihydrate
Molecular Formula: C21H31N3O5 Molecular Weight: 405.49
Melting Point: 148°C Boiling Point: 664.6°C
Solubility: H2O: ≥10 Mg/mL Density: 1.251 G/cm3
Risk Codes: R20/21/22 Safety Description: S22;S24/25
High Light:

Cas No 83915-83-7


Cas 83915 83 7 Lisinopril Dihydrate


83915 83 7 Cas Number

Lisinopril Cas No 83915-83-7 API; cardiovascular and cerebrovascular; receptor antagonist


Name Lisinopril
Synonyms (S)-1-(N2-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline dihydrate
Molecular Formula C21H31N3O5
Molecular Weight 405.49
CAS Registry Number 83915-83-7
EINECS Number 627-033-9
Melting point 148°C
Boiling point 664.6°C
Solubility H2O: ≥10 mg/mL
Density 1.251 g/cm3
Safety Description S22;S24/25
Risk Codes R20/21/22

Product Description:

Lisinopril is a lysine derivative of enalapril, which is the third generation angiotensin converting enzyme inhibitor. It is better than captopril and enalapril for moderate and severe patients. It has no direct effect on the heart, it will not cause arrhythmia, no central effect, no blood pressure rebound and other adverse reactions. It can be used in patients with hypertension, such as diabetes, asthma, peripheral vascular disease, mental illness and congestive heart failure, and other treatment drugs. It is effective for congestive heart failure in short term and long term.


Product Use:


Angiotensin converting enzyme inhibitors (ACEI) class of antihypertensive drugs.


Cas 83915-83-7 Lisinopril Dihydrate Pharmaceutical Receptor Antagonist Drugs  Cardiovascular Api 0Cas 83915-83-7 Lisinopril Dihydrate Pharmaceutical Receptor Antagonist Drugs  Cardiovascular Api 1


Product Catalogue:


Number Cas Name
1 41859-67-0 Bezafibrate
2 62571-86-2 Captopril
3 113665-84-2 Clopidogrel
4 75847-73-3 Enalapril
5 49562-28-9 Fenofibrate
6 25812-30-0 Gemfibrozil
7 21187-98-4 Glicalzide
8 138402-11-6 Irbesartan
9 83915-83-7 Lisinopril
10 75330-75-5 Lovastatin
11 79902-63-9 Simvastatin
12 87333-19-5 Ramipril
13 144701-48-4 Telmisartan
14 13649-88-2 Deflazacort
15 50-02-2 Dexamethasone
16 2135-17-3 Flumethasone
17 53-03-2 Prednisone



About us



Zhejiang chemical import and export co., LTD. (zhejiang), formerly known as zhejiang branch of China national chemical import and export corporation, was established in December 1980. In 1988, he was transferred from Sinochem Corporation to be in charge of Zhejiang Provincial Department of Commerce and was renamed Zhejiang Chemical Import and Export Company. In 2003, the company changed its name to Zhejiang Chemical Import and Export Co., Ltd after the reform of state-owned enterprise shareholding system.

In 2008, it was incorporated into Zhejiang International Trade Group (one of the top 500 enterprises in China) and became the core member of the group's business circulation sector. The registered capital of the company is 72.5 million yuan, of which 38% are owned by the state and 62% are owned by employees.
There are 195 employees in the company, more than 79% of whom have bachelor's degree, 36% of whom are graduate students, and more than 90% of the salesmen have pharmaceutical and chemical background. The company is mainly engaged in the import and export trade of pharmaceutical raw materials and intermediates, dyes, pesticides, basic chemicals, fine chemicals, food and feed additives, pharmaceutical preparations and other products. The company has established close economic and trade relations with more than 100 countries and regions around the world. The company has wholly-owned subsidiaries Ruike International Trade Co., Ltd., Zhejiang Ruikai Chemical Co., Ltd., Zhejiang Fukai Import and Export Co., Ltd., joint-stock enterprise Zhejiang Aotokang Pharmaceutical Group Co., Ltd.
In recent years, especially since the establishment of the new team in 2019, the company has adhered to the development led by the party building, energized by reform, and improved efficiency by management. The company has shown a steady upward momentum of development. In 2020, the company achieved revenue of 3.337 billion yuan, total profit of 56.12 million yuan, total import and export of 450 million dollars.

In 2019, the company was rated as China Council for the Promotion of International Trade (CCPIT) Recommended Certification Enterprise, Top 100 International Pharmaceutical Enterprises -- a high-quality supplier and partner in the international market; In 2020, Zhejiang Provincial Department of Commerce and other units rated as the province's epidemic prevention and medical materials import outstanding contribution enterprise, Zhejiang Provincial Tax Bureau identified as the export tax rebate enterprises.


Contact Details
William Wang

Phone Number : +86-13588430486

WhatsApp : +8613588430486